GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNY) » Definitions » Profitability Rank

Epigenomics AG (Epigenomics AG) Profitability Rank : 1 (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Epigenomics AG Profitability Rank?

Epigenomics AG has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Epigenomics AG's Operating Margin % for the quarter that ended in Jun. 2023 was -3,951.32%. As of today, Epigenomics AG's Piotroski F-Score is 2.


Competitive Comparison of Epigenomics AG's Profitability Rank

For the Diagnostics & Research subindustry, Epigenomics AG's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Profitability Rank Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Profitability Rank falls into.



Epigenomics AG Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Epigenomics AG has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Epigenomics AG's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=-3.003 / 0.076
=-3,951.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Epigenomics AG has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Epigenomics AG Profitability Rank Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines